Welcome to our dedicated page for REPLIGEN SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REPLIGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REPLIGEN's regulatory disclosures and financial reporting.
Repligen Corporation director Carrie Eglinton Manner reported compensation-related equity awards, not open-market trades. She was granted 995 restricted stock units, each representing a contingent right to receive one share of Repligen common stock. She also received stock options for 2,239 shares at an exercise price of $103.38 per share.
The restricted stock units and the stock option award each vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual meeting of shareholders. Following these grants, she holds 5,461 shares of common stock directly and 2,239 stock options.
Repligen Corp director Margaret Pax reported equity awards consisting of restricted stock units and stock options. She was granted 995 restricted stock units, each representing one future share of common stock, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting. She also received options for 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036, with the award vesting on the same schedule. Following the grant, she directly holds 3,011 shares of common stock.
Repligen Corp director Karen A. Dawes received equity compensation consisting of restricted stock units and stock options. She was granted 995 restricted stock units, each representing one share of common stock, which vest on the earlier of May 14, 2027 or the next annual shareholder meeting. She also received options for 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036. Following these awards, she directly holds 92,816 common shares. These are compensation grants, not open‑market purchases or sales.
REPLIGEN CORP director Glenn P. Muir reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of common stock, which vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting.
Muir also received stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036, with the same vesting schedule. Following these awards, he holds 40,051 shares of common stock directly and 2,239 stock options. The RSUs will be settled in shares after his service as a director ends, in line with his deferral election.
Repligen Corporation director Nicolas Barthelemy reported compensation-related equity grants. He was awarded 995 restricted stock units, each representing one share of Common Stock, and 2,239 stock options with an exercise price of $103.38 per share.
The RSUs and option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting. Barthelemy has elected to defer settlement of the RSUs under Repligen’s Deferred Compensation Plan for Non-Employee Directors, with shares to be delivered after his service as a director ends. Following these grants, he directly holds 5,436 shares of Common Stock and 2,239 options.
Repligen Corporation reported the results of its 2026 Annual Meeting of Stockholders. As of the March 16, 2026 record date, 56,399,274 common shares were outstanding, and 54,022,359 were represented in person or by proxy, establishing a quorum.
Stockholders elected nine directors, each receiving more votes “for” than “against.” They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
REPLIGEN CORP director Glenn P. Muir exercised stock options to acquire 2,434 shares of Common Stock. The options were exercised at $38.76 per share on May 7, 2026, and were fully vested and exercisable. Following the transaction, Muir directly holds 39,056 Common Stock shares. A corresponding derivative entry shows 2,434 Stock Option (Right to Buy) units exercised with an exercise price of $38.76 and an expiration date of May 18, 2027. No share sales or tax-withholding dispositions are reported in this Form 4.
Repligen Corp chief product officer Brian Robb had 334 common shares withheld on the release of restricted stock units, at a value of $126.43 per share. These shares were retained by the company to cover his tax obligations, not sold on the open market, leaving him with 7,985 shares held directly.
Repligen Corporation reports solid growth for the three months ended March 31, 2026, with total revenue of $194,255 (amounts in thousands), up 14.8% from 2025. Product revenue rose across all major franchises, including filtration, chromatography, process analytics and proteins.
Net income increased to $8,333, or $0.15 per diluted share, despite a $13,763 loss on the sale of Polymem S.A.S., which was partly offset by a $6,561 income tax benefit. Gross margin improved to 55.7% as higher volumes and mix more than covered cost increases.
Repligen ended the quarter with cash and cash equivalents of $582,650 and marketable securities of $201,881, supporting total assets of $2,930,772 and $600,000 principal of 1.00% Convertible Senior Notes due 2028. The company also began new restructuring initiatives and continues to work on remediating previously identified material weaknesses in internal control over financial reporting.
Repligen Corporation reported solid growth for the first quarter of 2026. Revenue reached $194.3M, up from $169.2M, a 15% increase, with 11% organic growth. GAAP diluted EPS rose to $0.15 from $0.10, while adjusted diluted EPS increased to $0.48 from $0.39.
GAAP gross margin was 55.7% and adjusted gross margin was 55.5%, with adjusted operating margin improving to 15.4%. Cash, cash equivalents and marketable securities totaled $785M at March 31, 2026. The company divested its non-core Polymem filtration business and launched a Transformation Office focused on margin expansion.
For full-year 2026, Repligen guides to adjusted revenue of $803M–$833M, implying 9%–13% reported and organic growth, and projects adjusted diluted EPS of $1.97–$2.05. Management also highlighted a new OEM partnership in China to expand local manufacturing access.